+ +

•  

   

     Western blot analysis using CD86 mouse mAb against L1210 (1) and MOLT-4 (2) cell lysate.    

  
  

CD86. also known as B7-2. is a co-stimulatory protein belonging to the B7 family of immune checkpoint molecules. It is primarily expressed on antigen-presenting cells (APCs), such as dendritic cells, macrophages, and activated B cells, where it interacts with CD28 and CTLA-4 receptors on T cells to regulate immune responses. The binding of CD86 to CD28 provides a critical secondary signal for T cell activation, while its interaction with CTLA-4 delivers inhibitory signals to suppress T cell function, maintaining immune tolerance. Dysregulation of CD86 is implicated in autoimmune diseases, transplant rejection, and cancer immune evasion.

CD86-targeting antibodies are tools or therapeutics designed to modulate these interactions. In cancer immunotherapy, blocking CD86-CTLA-4 engagement (e.g., via anti-CTLA-4 antibodies like ipilimumab) enhances anti-tumor immunity by sustaining T cell activation. Conversely, agonist antibodies that promote CD86-CD28 signaling may boost immune responses in chronic infections or vaccines. Inhibitory antibodies against CD86 itself are explored for autoimmune conditions to dampen pathogenic T cell activity. Structurally, CD86 antibodies typically recognize extracellular IgV or IgC domains of the protein. Challenges include balancing therapeutic efficacy with immune-related adverse events, given CD86’s dual role in activation and suppression. Research continues to optimize specificity and delivery strategies for clinical applications.